Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by the small intestine upon food intake. GLP-1 enhances insulin secretion, suppresses glucagon release, and promotes satiety, resulting in reduced food consumption and subsequent weight loss. Endogenous GLP-1 has a very short half-life an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/5/622 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711523601055744 |
|---|---|
| author | Yaswanth Kuthati Venkata Naga Goutham Davuluri Chih-Shung Wong |
| author_facet | Yaswanth Kuthati Venkata Naga Goutham Davuluri Chih-Shung Wong |
| author_sort | Yaswanth Kuthati |
| collection | DOAJ |
| description | Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by the small intestine upon food intake. GLP-1 enhances insulin secretion, suppresses glucagon release, and promotes satiety, resulting in reduced food consumption and subsequent weight loss. Endogenous GLP-1 has a very short half-life and is rapidly degraded by the enzyme dipeptidyl-peptidase-IV (DPP-4). To address this limitation, GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors (DPP-4is) were developed and have demonstrated potency in clinical practice. In recent years, GLP-1RA and DPP4-i therapies are known to have pleiotropic effects, such as a reduction in oxidative stress, autophagy regulation, metabolic reprogramming, enhancement of anti-inflammatory signaling, regulation of gene expression, and being neuroprotective. These effects imply a therapeutic perspective for GLP-1RA and DPP-4i therapies in neuropathic pain treatment. Preclinical and clinical studies increasingly support the hypothesis that these therapies may alleviate neuropathic pain by targeting multiple mechanisms that induce neuropathic pain, such as inflammation, oxidative stress, and mitochondrial dysfunction. This review explores the mechanisms by which GLP-1RAs and DPP-4is alleviate neuropathic pain. It also highlights current advancements in incretin research, focusing on the therapeutic effects of GLP-1RAs and DPP-4-is for neuropathic pain. |
| format | Article |
| id | doaj-art-d642224f3b6c4e4ca8a164ba38b5039c |
| institution | DOAJ |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-d642224f3b6c4e4ca8a164ba38b5039c2025-08-20T03:14:36ZengMDPI AGBiomolecules2218-273X2025-04-0115562210.3390/biom15050622Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical ImplicationsYaswanth Kuthati0Venkata Naga Goutham Davuluri1Chih-Shung Wong2Department of Anesthesiology, Cathay General Hospital, Taipei 10630, TaiwanDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USADepartment of Anesthesiology, Cathay General Hospital, Taipei 10630, TaiwanGlucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by the small intestine upon food intake. GLP-1 enhances insulin secretion, suppresses glucagon release, and promotes satiety, resulting in reduced food consumption and subsequent weight loss. Endogenous GLP-1 has a very short half-life and is rapidly degraded by the enzyme dipeptidyl-peptidase-IV (DPP-4). To address this limitation, GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors (DPP-4is) were developed and have demonstrated potency in clinical practice. In recent years, GLP-1RA and DPP4-i therapies are known to have pleiotropic effects, such as a reduction in oxidative stress, autophagy regulation, metabolic reprogramming, enhancement of anti-inflammatory signaling, regulation of gene expression, and being neuroprotective. These effects imply a therapeutic perspective for GLP-1RA and DPP-4i therapies in neuropathic pain treatment. Preclinical and clinical studies increasingly support the hypothesis that these therapies may alleviate neuropathic pain by targeting multiple mechanisms that induce neuropathic pain, such as inflammation, oxidative stress, and mitochondrial dysfunction. This review explores the mechanisms by which GLP-1RAs and DPP-4is alleviate neuropathic pain. It also highlights current advancements in incretin research, focusing on the therapeutic effects of GLP-1RAs and DPP-4-is for neuropathic pain.https://www.mdpi.com/2218-273X/15/5/622glucagon-like peptide-1dipeptidyl-peptidase-IV inhibitorsneuropathic painoxidative stressinflammation |
| spellingShingle | Yaswanth Kuthati Venkata Naga Goutham Davuluri Chih-Shung Wong Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications Biomolecules glucagon-like peptide-1 dipeptidyl-peptidase-IV inhibitors neuropathic pain oxidative stress inflammation |
| title | Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications |
| title_full | Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications |
| title_fullStr | Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications |
| title_full_unstemmed | Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications |
| title_short | Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications |
| title_sort | therapeutic effects of glp 1 receptor agonists and dpp 4 inhibitors in neuropathic pain mechanisms and clinical implications |
| topic | glucagon-like peptide-1 dipeptidyl-peptidase-IV inhibitors neuropathic pain oxidative stress inflammation |
| url | https://www.mdpi.com/2218-273X/15/5/622 |
| work_keys_str_mv | AT yaswanthkuthati therapeuticeffectsofglp1receptoragonistsanddpp4inhibitorsinneuropathicpainmechanismsandclinicalimplications AT venkatanagagouthamdavuluri therapeuticeffectsofglp1receptoragonistsanddpp4inhibitorsinneuropathicpainmechanismsandclinicalimplications AT chihshungwong therapeuticeffectsofglp1receptoragonistsanddpp4inhibitorsinneuropathicpainmechanismsandclinicalimplications |